miR‑616 promotes breast cancer migration and invasion by targeting TIMP2 and regulating MMP signaling

Yuan,Chao

doi:10.3892/ol.2019.10546

miR‑616 promotes breast cancer migration and invasion by targeting TIMP2 and regulating MMP signaling

Authors:
- Chao Yuan
View Affiliations

Affiliations: Department of Breast Surgery, Dezhou No. 2 People's Hospital, Dezhou, Shandong 253000, P.R. China
Published online on: June 28, 2019 https://doi.org/10.3892/ol.2019.10546
Pages: 2348-2355
Copyright: © Yuan . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is one of the most frequently diagnosed cancer types in females worldwide. The aim of the present study was to investigate the expression levels, functional role and molecular mechanism of microRNA‑616 (miR‑616) in the progression of breast cancer cells. The relative expression levels of miR‑616 in breast cancer cell lines and tumor tissues of 30 patients with breast cancer were analyzed using reverse transcription‑quantitative PCR (RT‑qPCR). Cell transfection was used to upregulate and downregulate the expression of miR‑616 in MCF‑7 and MDA‑MB‑231 cells, respectively. The regulatory effect of miR‑616 on tissue inhibitor of metalloproteinases 2 (TIMP2) expression was also analyzed by dual‑luciferase reporter assay, western blot analysis and RT‑qPCR. The results of RT‑qPCR analysis demonstrated significantly higher expression levels of miR‑616 in tumor tissues and cancer cell lines compared with normal tissues and a normal epithelial cell line. In addition, overexpression of miR‑616 significantly promoted MCF‑7 cell proliferation, migration and invasion. By contrast, miR‑616 silencing was associated with the opposite effects in MDA‑MB‑231 cells. Furthermore, the present study demonstrated that miR‑616 could positively regulate the expression of matrix metalloproteinases (MMP)2 and MMP9, both at the mRNA and protein level. TIMP2 was further confirmed as a direct target of miR‑616. Finally, the current study demonstrated that TIMP2 silencing rescued the proliferation and invasion capabilities and the expression levels of MMP2 and MMP9 in cells that were treated with the miR‑616 inhibitor. In conclusion, the present data suggested that the miR‑616/TIMP2/MMPs axis may serve an important role in the progression of breast cancer and may be a potential therapeutic target for this disease.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
3	Valastyan S and Weinberg RA: Tumor metastasis: Molecular insights and evolving paradigms. Cell. 147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
4	Weigelt B, Peterse JL and van't Veer LJ: Breast cancer metastasis: Markers and models. Nat Rev Cancer. 5:591–602. 2005. View Article : Google Scholar : PubMed/NCBI
5	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
6	Shen J, Stass SA and Jiang F: MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett. 329:125–136. 2013. View Article : Google Scholar : PubMed/NCBI
7	Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009. View Article : Google Scholar : PubMed/NCBI
8	Piasecka D, Braun M, Kordek R, Sadej R and Romanska H: MicroRNAs in regulation of triple-negative breast cancer progression. J Cancer Res Clin Oncol. 144:1401–1411. 2018. View Article : Google Scholar : PubMed/NCBI
9	Hu W, Tan C, He Y, Zhang G, Xu Y and Tang J: Functional miRNAs in breast cancer drug resistance. Onco Targets Ther. 11:1529–1541. 2018. View Article : Google Scholar : PubMed/NCBI
10	Wu ZH, Lin C, Liu CC, Jiang WW, Huang MZ, Liu X and Guo WJ: MiR-616-3p promotes angiogenesis and EMT in gastric cancer via the PTEN/AKT/mTOR pathway. Biochem Biophys Res Commun. 501:1068–1073. 2018. View Article : Google Scholar : PubMed/NCBI
11	Bai QL, Hu CW, Wang XR, Shang JX and Yin GF: MiR-616 promotes proliferation and inhibits apoptosis in glioma cells by suppressing expression of SOX7 via the Wnt signaling pathway. Eur Rev Med Pharmacol Sci. 21:5630–5637. 2017.PubMed/NCBI
12	Wang D, Cao Q, Qu M, Xiao Z, Zhang M and Di S: MicroRNA-616 promotes the growth and metastasis of non-small cell lung cancer by targeting SOX7. Oncol Rep. 38:2078–2086. 2017. View Article : Google Scholar : PubMed/NCBI
13	Zhang D, Zhou P, Wang W, Wang X, Li J, Sun X and Zhang L: MicroRNA-616 promotes the migration, invasion and epithelial-mesenchymal transition of HCC by targeting PTEN. Oncol Rep. 35:366–374. 2016. View Article : Google Scholar : PubMed/NCBI
14	Ma S, Chan YP, Kwan PS, Lee TK, Yan M, Tang KH, Ling MT, Vielkind JR, Guan XY and Chan KW: MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2. Cancer Res. 71:583–592. 2011. View Article : Google Scholar : PubMed/NCBI
15	Chen Z, Zhu J, Zhu Y and Wang J: MicroRNA-616 promotes the progression of ovarian cancer by targeting TIMP2. Oncol Rep. 39:2960–2968. 2018.PubMed/NCBI
16	Chien YC, Liu LC, Ye HY, Wu JY and Yu YL: EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway. Am J Cancer Res. 8:422–434. 2018.PubMed/NCBI
17	Chao Y, Hu K, Wang X and Wang L: MicroRNA-552 promotes migration and invasion of osteosarcoma through targeting TIMP2. Biochem Biophys Res Commun. 511:63–68. 2019. View Article : Google Scholar : PubMed/NCBI
18	Yin S, Zhang Q, Wang Y, Li S and Hu R: MicroRNA-130a regulated by HPV18 E6 promotes proliferation and invasion of cervical cancer cells by targeting TIMP2. Exp Ther Med. 17:2837–2846. 2019.PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Ren F, Tang R, Zhang X, Madushi WM, Luo D, Dang Y, Li Z, Wei K and Chen G: Overexpression of MMP family members functions as prognostic biomarker for breast cancer patients: A systematic review and meta-analysis. PLoS One. 10:e01355442015. View Article : Google Scholar : PubMed/NCBI
21	Tjomsland V, Pomianowska E, Aasrum M, Sandnes D, Verbeke CS and Gladhaug IP: Profile of MMP and TIMP expression in human pancreatic stellate cells: Regulation by IL-1α and TGFβ and implications for migration of pancreatic cancer cells. Neoplasia. 18:447–456. 2016. View Article : Google Scholar : PubMed/NCBI
22	Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
23	Pasquinelli AE: MicroRNAs and their targets: Recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 13:271–282. 2012. View Article : Google Scholar : PubMed/NCBI
24	Lu L, Mao X, Shi P, He B, Xu K, Zhang S and Wang J: MicroRNAs in the prognosis of triple-negative breast cancer: A systematic review and meta-analysis. Medicine (Baltimore). 96:e70852017. View Article : Google Scholar : PubMed/NCBI
25	Kurzawski M, Kaczmarek M, Kłysz M, Malinowski D, Kazienko A, Kurzawa R and Droździk M: MMP2, MMP9 and TIMP2 polymorphisms affect sperm parameters but not fertility in Polish males. Andrologia. 49:2017. View Article : Google Scholar : PubMed/NCBI
26	Kim HJ, Park CI, Park BW, Lee HD and Jung WH: Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J. 47:333–342. 2006. View Article : Google Scholar : PubMed/NCBI